Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 15 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The Medical Total Solutions business is expected to steadily capture hospitals’ demand for medical equipment replacements, while expenses are also expected to come in below assumptions. In addition, the Faskia Group’s minimally invasive medical equipment sales business and hearing aid sales business have both performed above expectations.
| Item | Details |
|---|---|
| Net Sales | ¥44,500 million → ¥48,000 million（+7.9%） |
| Operating profit | ¥680 million → ¥890 million（+30.9%） |
| Ordinary income | ¥610 million → ¥820 million（+34.4%） |
| Profit attributable to owners of the parent | ¥230 million → ¥400 million（+73.9%） |
| Net income per share | 38.84 yen and sen → 67.55 yen and sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 15 May 2026 |
| Previous-period results | Fiscal Period Covered Fiscal year ended September 2025 / Net Sales JPY 21,489 million / Operating profit ¥288 million / Ordinary income ¥308 million / Profit attributable to owners of the parent ¥152 million / Net income per share ¥25.86 |
| Reason for the revision | The Medical Total Solutions business is expected to steadily capture hospitals’ demand for medical equipment replacements, while expenses are also expected to come in below assumptions. In addition, the Faskia Group’s minimally invasive medical equipment sales business and hearing aid sales business have both performed above expectations. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Medical Total Solutions business is expected to capture hospitals’ demand for medical equipment replacements, while expenses are also expected to come in below assumptions. In addition, the minimally invasive medical equipment sales business and hearing aid sales business of the Faskia Group, which was made a subsidiary, have both performed above expectations.